From a clinical perspective, BRAF-mutated colorectal carcinomas (CRCs) are frequently addicted to this mitochondrial survival pathway, resistant to apoptosis and poorly responsive to standard chemotherapeutics and EGFR monoclonals [9–11]. This evidence concerns the gene BRAF and colorectal carcinoma.